(Q64380394)

2

0 references

L Johnson

3

0 references

G Brooks

4

0 references

A Sampson-Johannes

5

0 references

A Williams

6

0 references

L Hawkins

7

0 references

D Kirn

Experimental Therapy of Human Glioma by Means of a Genetically Engineered Virus Mutant

8

0 references

language of work or name

English

0 references

publication date

October 2000

0 references

published in

Nature Medicine

0 references

volume

6

0 references

page(s)

1134-9

0 references

issue

10

0 references

cites work

1 reference

7 January 2021

An adenovirus mutant that replicates selectively in p53-deficient human tumor cells

1 reference

7 January 2021

Replication-selective microbiological agents: fighting cancer with targeted germ warfare

1 reference

7 January 2021

Selective infection and cytolysis of human head and neck squamous cell carcinoma with sparing of normal mucosa by a cytotoxic herpes simplex virus type 1 (G207).

1 reference

7 January 2021

Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas

1 reference

7 January 2021

ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents

1 reference

7 January 2021

A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo.

1 reference

7 January 2021

Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial

1 reference

7 January 2021

Association between an oncogene and an anti-oncogene: the adenovirus E1A proteins bind to the retinoblastoma gene product

1 reference

7 January 2021

Identification of separate domains in the adenovirus E1A gene for immortalization activity and the activation of virus early genes

1 reference

7 January 2021

Cellular targets for transformation by the adenovirus E1A proteins

1 reference

7 January 2021

Sequences in E1A proteins of human adenovirus 5 required for cell transformation, repression of a transcriptional enhancer, and induction of proliferating cell nuclear antigen.

1 reference

7 January 2021

1 reference

7 January 2021

Targeting the replication of adenoviral gene therapy vectors to lung cancer cells: the importance of the adenoviral E1b-55kD gene

1 reference

7 January 2021

ONYX-015: clinical data are encouraging

1 reference

7 January 2021

a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer

1 reference

7 January 2021

mUBC9, a novel adenovirus E1A-interacting protein that complements a yeast cell cycle defect

1 reference

7 January 2021

Degradation of E2F by the ubiquitin-proteasome pathway: regulation by retinoblastoma family proteins and adenovirus transforming proteins

1 reference

7 January 2021

Phosphorylation of adenovirus E1A proteins by the p34cdc2 protein kinase

1 reference

7 January 2021

Role of phosphorylation near the amino terminus of adenovirus type 5 early region 1A proteins.

1 reference

7 January 2021

Barriers to drug delivery in solid tumors

1 reference

7 January 2021

Replication-selective adenoviruses as oncolytic agents

1 reference

7 January 2021

Adenovirus proteins from both E1B reading frames are required for transformation of rodent cells by viral infection and DNA transfection

1 reference

7 January 2021